Lyra Therapeutics

Watertown, United States Founded: 2005 • Age: 21 yrs
Small molecule therapeutics for ENT diseases are developed.
Request Access

About Lyra Therapeutics

Lyra Therapeutics is a company based in Watertown (United States) founded in 2005 by George Whitesides and Robert Langer.. Lyra Therapeutics has raised $127.61 million across 12 funding rounds from investors including HHS, RA Capital and Perceptive Advisors. The company has 30 employees as of December 31, 2024. Lyra Therapeutics operates in a competitive market with competitors including Insulet, Decibel Therapeutics, TriSalus Life Sciences, Credence MedSystems and Akouos, among others.

  • Headquarter Watertown, United States
  • Employees 30 as on 31 Dec, 2024
  • Founders George Whitesides, Robert Langer
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Lyra Therapeutics, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $1.53 M
    -1.54
    as on Dec 31, 2024
  • Net Profit
    $-93.44 M
    -49.07
    as on Dec 31, 2024
  • EBITDA
    $-60.26 M
    7.64
    as on Dec 31, 2024
  • Total Equity Funding
    $127.61 M (USD)

    in 12 rounds

  • Latest Funding Round
    $50 M (USD), Post-IPO

    Jun 09, 2023

  • Investors
    HHS

    & 9 more

  • Employee Count
    30

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Lyra Therapeutics

Lyra Therapeutics is a publicly listed company on the NASDAQ with ticker symbol LYRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: LYRA . Sector: Health technology · USA

Funding Insights of Lyra Therapeutics

Lyra Therapeutics has successfully raised a total of $127.61M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 12
  • Last Round Post-IPO — $50.0M
  • First Round

    (26 Oct 2011)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2023 Amount Post-IPO - Lyra Therapeutics Valuation

investors

Jan, 2020 Amount Series B - Lyra Therapeutics Valuation Perceptive Advisors
Sep, 2018 Amount Series B - Lyra Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Lyra Therapeutics

Lyra Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, RA Capital and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Health-tech companies are targeted for venture capital investments.
Founded Year Domain Location
US focused venture capital firm
Founded Year Domain Location
US focused seed to growth stage VC firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Lyra Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Lyra Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Lyra Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Lyra Therapeutics

Lyra Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Decibel Therapeutics, TriSalus Life Sciences, Credence MedSystems and Akouos, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Wearable insulin infusion systems are developed for diabetes patients.
domain founded_year HQ Location
Medicines are developed to protect, repair, and restore hearing capacity.
domain founded_year HQ Location
Developer of drug delivery devices to treat cancers
domain founded_year HQ Location
Developer of smart devices for drug delivery
domain founded_year HQ Location
Developer of gene therapies to restore and preserve hearing capabilities in genetically defined populations
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Lyra Therapeutics

Frequently Asked Questions about Lyra Therapeutics

When was Lyra Therapeutics founded?

Lyra Therapeutics was founded in 2005 and raised its 1st funding round 6 years after it was founded.

Where is Lyra Therapeutics located?

Lyra Therapeutics is headquartered in Watertown, United States.

Who is the current CEO of Lyra Therapeutics?

Maria Palasis is the current CEO of Lyra Therapeutics.

Is Lyra Therapeutics a funded company?

Lyra Therapeutics is a funded company, having raised a total of $127.61M across 12 funding rounds to date. The company's 1st funding round was a Series B of $29.5M, raised on Oct 26, 2011.

How many employees does Lyra Therapeutics have?

As of Dec 31, 2024, the latest employee count at Lyra Therapeutics is 30.

What is the annual revenue of Lyra Therapeutics?

Annual revenue of Lyra Therapeutics is $1.53M as on Dec 31, 2024.

What does Lyra Therapeutics do?

Lyra therapeutics is developing small molecule based therapeutics for ear, nose, and throat (ENT) diseases. The companys proprietary product platform is a transmucosal therapeutic system which comprises of drugs that target ear, nose, and throat diseases and administered through a polymeric matrix. The companys lead product candidate LYR-210 used against chronic rhinosinusitis is used to deliver a long-acting formulation of an approved steroid, mometasone furoate, deep into the sinonasal tissues. It has completed the Phase 1 clinical trials. It can be used in patients both with and without nasal polyps.

Who are the top competitors of Lyra Therapeutics?

Lyra Therapeutics's top competitors include Insulet, Decibel Therapeutics and TriSalus Life Sciences.

Is Lyra Therapeutics publicly traded?

Yes, Lyra Therapeutics is publicly traded on NASDAQ under the ticker symbol LYRA.

Who are Lyra Therapeutics's investors?

Lyra Therapeutics has 10 investors. Key investors include HHS, RA Capital, Perceptive Advisors, ArrowMark Partners, and Polaris Partners.

What is Lyra Therapeutics's ticker symbol?

The ticker symbol of Lyra Therapeutics is LYRA on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available